 |
Indication & Dosage |
| |
| |
| Oral |
| MENORRHAGIA |
| Adult:
2.5-10 mg daily for 5-10 days starting on the 16th-21st day of the menstrual cycle. Repeat for 2 cycles. |
| |
| Oral |
| MILD TO MODERATE ENDOMETRIOSIS |
| Adult:
10 mg tid. |
| |
| Oral |
| AS PROGESTOGEN COMPONENT IN MENOPAUSAL HRT |
| Adult:
Dosage dependant on oestrogen component of therapy, several regimens are used: 1.5 mg, 2.5 mg or 5 mg daily; 5 or 10 mg daily for 12-14 days of a 28-day cycle; 20 mg daily for 14 days of a 91-day cycle. |
| |
| Oral |
| BREAST CANCER |
| Adult:
0.4-1.5 g daily. Max: 2 g daily. |
| |
| Oral |
| PALLIATIVE TREATMENT OF ENDOMETRIAL AND RENAL CARCINOMA |
| Adult:
200-600 mg daily. |
| |
| Oral |
| SECONDARY AMENORRHOEA |
| Adult:
2.5-10 mg daily for 5-10 days. Repeated for 3 cycles. |
| |
| Oral |
| PALLIATIVE TREATMENT OF PROSTATIC CARCINOMA |
| Adult:
100-600 mg daily. |
| |
| Intramuscular |
| MENORRHAGIAENDOMETRIOSIS |
| Adult:
50 mg wkly or 100 mg every 2 wk. |
| |
| Intramuscular |
| MENORRHAGIACONTRACEPTION |
| Adult:
150 mg every 12 wk. |
| |
| Intramuscular |
| BREAST CANCER |
| Adult:
0.5-1 g daily for first 4 wk. Maintenance 0.5 g twice wkly. |
| |
| Intramuscular |
| PALLIATIVE TREATMENT OF ENDOMETRIAL AND RENAL CARCINOMA |
| Adult:
Initially 0.4-1 g wkly. Reduce as necessary, maintenance may be as low as 0.4 g mthly. |
| |
| Intramuscular |
| MENORRHAGIAPALLIATIVE TREATMENT OF PROSTATIC CARCINOMA |
| Adult:
0.5 g twice wkly for first 3 mth. Maintenance 0.5 g wkly. |
| |
| Subcutaneous |
| ENDOMETRIOSIS |
| Adult:
104 mg every 12-14 wk. |
| |
| Subcutaneous |
| CONTRACEPTION |
| Adult:
104 mg every 12-14 wk. |
|
| |
|
| Administration |
May be taken with or without food. (Incidence of minor indigestion may increase as dose increases. Take w/ meals if necessary.) |
| |
|
| Precautions |
Patients with depression, DM, epilepsy, asthma, migraine, hypertension, renal or cardiac dysfunction. Monitor patient closely for loss of vision, proptosis, diplopia and thromboembolic disorders. Lactation. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Depression, fluid retention. Fatigue, insomnia, dizziness, headache, nausea; breast tenderness; wt gain/loss, anorexia; cholestatic jaundice; pain at Inj site. |
| |
|
| Adverse Drug Reactions |
Thrombophlebitis and pulmonary embolism. |
| |
|
| Interactions |
Aminoglutethimide and enzyme-inducing drugs (e.g. carbamazepine, griseofulvin, phenobarbital, rifampicin, phenytoin) may reduce plasma concentrations leading to reduced efficacy. Additional measures required when medroxyprogesterone is used for contraception during coadministration with these drugs. |
| |
|
|
|
